A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of SAR236553/REGN727 on the occurrence of cardiovascular events in patients who have recently experienced acute coronary syndrome.
In the ODYSSEY trial, eligible patients are after a cardiac event (< 52 weeks), suffer from hyperlipidemia (high cholesterol) and currently taking maximum tolerated doses of statin. The goal of this trial is to show that the drug not only lowers LDL but also reduces the risk of heart attack/stroke/death.
The research medication is one of the first of a new class of drugs called PCSK9 inhibitors called alirocumab (trade name Praluent). PCSK9 inhibits a protein in the body (PCSK9) that helps regulate cholesterol.
Neal Perlmutter, MD
Clinical Trial Categories
Research Study Staff at 425-688-5407
(CONTACT FORM HERE)
Overlake Medical Center
1035 116th Ave. NE
Bellevue, WA 98004